Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Capital Expenditures (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Capital Expenditures for 6 consecutive years, with $171000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 94.89% to $171000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, up 15.22% year-over-year, with the annual reading at $4.4 million for FY2025, 15.22% up from the prior year.
  • Capital Expenditures for Q4 2025 was $171000.0 at TScan Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Capital Expenditures was $5.0 million in Q2 2021, with the low at -$5.4 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $490250.0, with a median of $387500.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures plummeted 2469.57% in 2021, then soared 621.45% in 2023.
  • Over 5 years, Capital Expenditures stood at -$599000.0 in 2021, then skyrocketed by 78.63% to -$128000.0 in 2022, then tumbled by 1756.25% to -$2.4 million in 2023, then surged by 240.78% to $3.3 million in 2024, then plummeted by 94.89% to $171000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $171000.0, $1.4 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.